This article is more than 5 years old. Information may no longer be current.
Latest diabetes news, research from the AACE Annual Scientific and Clinical Congress
Researchers presented data and clinical updates at the American Association of Clinical Endocrinologists Annual Scientific and Clinical Congress in Orlando, Florida.
Live coverage from the Endocrine Today team featured news from the conference, onsite video interviews with leading experts and research implications on patient care and practice.
Healio Internal Medicine presents five of the latest updates in diabetes from the meeting.
Inpatient self-management for diabetes effective
Inpatients with diabetes may effectively manage their diabetes and achieve diabetes care that is as effective as standard nursing care.
“Inpatient management of diabetes consumes significant staff resources,” Peter Thule, MD, professor of medicine in the Department of Medicine at Emory University, and colleagues wrote in an abstract presented at the meeting. “In contrast to outpatient strategies, patients are typically excluded from glycemic management when hospitalized.” Read more.
AACE/ACE app offers clinical guidance for management of type 2 diabetes
AACE and the American College of Endocrinology (ACE) announced the worldwide availability of an in-depth, point-of-care app designed to offer clinical practice guidance for the management of type 2 diabetes.
The free app, based on the AACE/ACE comprehensive diabetes management algorithm, includes recommendations for evidence-based approaches to treatment based on a patient’s individual risks and complications. Read more.
Speaker: Preparation is key to diabetes management during air travel
The mismanagement of diabetes during air travel can lead to adverse consequences, including hypoglycemia during eastward travel and hyperglycemia or diabetic ketoacidosis during westward travel, according to a speaker here.
“Travel disrupts people’s normal routines, whether that is their diet or their [insulin]-dosing times,” Rahul Suresh, MD, MS, a second-year resident at the University of Texas Medical Branch in Galveston, Texas, said during a press conference. “In order to avoid complications with medication dosing, insulin and other diabetes medicines have to be taken at certain times, with respect to carbohydrate intake and overall calorie intake.” Read more.
Addition of Farxiga to insulin, liraglutide improved glycemia in type 1 diabetes
Patients with type 1 diabetes treated with insulin and liraglutide with the addition of Farxiga had significant improvements in glycemia.
Farxiga (dapagliflozin, Astra Zeneca) is an SGLT2 inhibitor that blocks the reabsorption of glucose by the kidney, increases glucose excretion and lowers blood glucose levels. Read more.
Liragluti de as adjunct to insulin reduced HbA1c, BMI
Patients with type 1 diabetes treated with liraglutide as an adjunct to insulin had significantly reduced HbA1c and BMI, according to presented findings.
“Insulin is essential for patients with type 1 diabetes,” the researchers wrote. “With the obesity epidemic, obesity and insulin resistance are no longer uncommon features in these patients. This has led to increased interest in the role of glucagon-like receptor agonists as adjunctive therapy in this patient population.” Read more.